Needham analyst Mayank Tandon reiterates Genpact (NYSE:G) with a Buy and maintains $56 price target.
JP Morgan Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $17
JP Morgan analyst Tessa Romero maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and lowers the price target from $19 to $17.